DeVos Heart and Lung Transplantation Program Spectrum Health, Michigan State University, Grand Rapids, Mich.
Johns Hopkins School of Public Health, Baltimore, Md.
J Thorac Cardiovasc Surg. 2015 Jan;149(1):291-6. doi: 10.1016/j.jtcvs.2014.08.072. Epub 2014 Sep 17.
Improvements in technology have led to a resurgence in the use of extracorporeal membrane oxygenation as a bridge to lung transplantation. By using a national registry, we sought to evaluate how short-term survival has evolved using this strategy.
With the use of the United Network for Organ Sharing database, we analyzed data from 12,458 adults who underwent lung transplantation between 2000 and 2011. Patients were categorized into 2 cohorts: 119 patients who were bridged to transplantation using extracorporeal membrane oxygenation and 12,339 patients who were not. The study period was divided into four 3-year intervals: 2000 to 2002, 2003 to 2005, 2006 to 2008, and 2009 to 2011. With Kaplan-Meier analysis, 1-year survival was compared for the 2 cohorts of patients in each of the time periods. A propensity score-adjusted Cox regression model was used to estimate the risk of 1-year mortality.
Of the total number of recipients, 4 (3.4%) were bridged between 2000 and 2002, 17 (14.3%) were bridged between 2003 and 2005, 31 (26.1%) were bridged between 2006 and 2008, and 67 were bridged (56.3%) between 2009 and 2011. Recipients bridged using extracorporeal membrane oxygenation were more likely to be younger and diabetic and to have higher serum creatinine and bilirubin levels. The 1-year survival for those bridged with extracorporeal membrane oxygenation was significantly lower in subsequent periods: 25.0% versus 81.0% (2000-2002), 47.1% versus 84.2% (2006-2008), and 74.4% versus 85.7% (2009-2011). However, this survival progressively increased with each period, as did the number of patients bridged using extracorporeal membrane oxygenation.
Short-term survival with the use of extracorporeal membrane oxygenation as a bridge to lung transplantation has significantly improved over the past few years.
技术的进步使得体外膜肺氧合作为肺移植桥接再次得到广泛应用。本研究通过使用国家登记系统,旨在评估使用这种策略的短期生存率的变化情况。
利用美国器官共享网络数据库,我们分析了 2000 年至 2011 年间接受肺移植的 12458 例成人患者的数据。患者分为两组:119 例使用体外膜肺氧合进行桥接治疗的患者和 12339 例未使用的患者。研究期间分为四个 3 年间隔期:2000 年至 2002 年、2003 年至 2005 年、2006 年至 2008 年和 2009 年至 2011 年。采用 Kaplan-Meier 分析比较了每个时间段两组患者的 1 年生存率。使用倾向评分调整的 Cox 回归模型估计 1 年死亡率的风险。
在所有受者中,2000 年至 2002 年有 4 例(3.4%)接受桥接治疗,2003 年至 2005 年有 17 例(14.3%),2006 年至 2008 年有 31 例(26.1%),2009 年至 2011 年有 67 例(56.3%)接受桥接治疗。使用体外膜肺氧合进行桥接治疗的患者更可能年龄较小且患有糖尿病,同时血清肌酐和胆红素水平更高。随后各时间段使用体外膜肺氧合进行桥接治疗的患者 1 年生存率明显较低:2000 年至 2002 年为 25.0%比 81.0%,2006 年至 2008 年为 47.1%比 84.2%,2009 年至 2011 年为 74.4%比 85.7%。然而,随着时间的推移,这种生存率逐渐提高,接受体外膜肺氧合桥接治疗的患者数量也逐渐增加。
体外膜肺氧合作为肺移植桥接的短期生存率在过去几年中显著提高。